Adverse Drug Events Observed With The Novel Sodium/Glucose Co-Transporter 2 Inhibitor Ipragliflozin For The Treatment Of Patients With Type 2 Diabetes Mellitus: A Systematic Review And Meta-Analysis Of Randomized Studies
The above summary slide represents
the opinions of the authors. For a full list of declarations, including funding
and author disclosure statements, please see the full text online (see “read
the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2020.